慢性骨髓性白血病的药物治疗进展:超越了氨酸激酶抑制剂
Alessandro Costa1, Emilia Scalzulli2, Ida Carmosino2
1Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Expert opinion on pharmacotherapy
|March 15, 2024
概括
新的慢性髓性白血病 (CML) 治疗方法旨在通过向白血病干细胞 (LSCs) 来克服氨酸激酶抑制剂 (TKI) 耐药性. 研究探索免疫疗法和新型化合物,以改善CML患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKIs) 在治疗慢性髓性白血病 (CML) 中是成功的.
- 一部分CML患者在停止TKI治疗后发展出耐药性或复发.
- 这种耐药性与费城染色体阳性 (Ph+) 白血病干细胞 (LSCs) 相关,目前的疗法无法完全向这些干细胞.
研究的目的:
- 审查目前和新兴的CML治疗策略,超出标准的TKI抑制.
- 突出针对白血病干细胞 (LSCs) 和其微观环境的新方法.
主要方法:
- 审查当前的药理学进展和正在进行的CML治疗的调查.
- 探索包括免疫疗法,表观遗传调制和微环境干扰在内的替代策略.
- 对向LSC,自我更新通路和特定表面受体 (如CD26.6) 的化合物进行分析.
主要成果:
- 除了BCR::ABL1抑制之外的创新方法正在研究中.
- 免疫疗法 (例如,干扰素-α) 和调动Ph + LSCs的化合物显示出潜在的免疫疗法.
- 许多新的策略仍然包含技术知识,建议采用组合方法.
结论:
- 新兴的治疗前景有可能在CML治疗中取得重大进展.
- 针对Ph + LSC及其利基对于克服TKI抵抗至关重要.
- 需要进一步的研究,以优化新的策略,以提高CML管理和停药率.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524


